TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07227103: A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression:

Sponsor: NeuroRx, Inc. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$15,147,520

Rescue Site Savings

+$9,987,896

Unlock Full NCT07227103 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07227103 Rescue Dossier →